entertainment -WSS

entertainment

author：leisure time 2025-08-24 19:14:02 - browse：37

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How I helped Pfizer think through the ethics of Viagra

WSS

A controversial new treatment promises to make little people taller

Biden will tout long

Medicare slashes safety net hospital payments by nearly $1 billion

When waiting feels immoral: Empathy in the emergency department

The a glaring gap in research on serious mental illness and primary care

The UK government moves asylum

leisure time

entertainment

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Group behind ProMed defends move to subscription

Psychedelics group wrestles with new pharma identity

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pharma showers House GOP doctor with campaign cash

Affirmative action in medical school literally saved lives

Study links childhood stress with decline in older age

23andMe had bad news about my health. I wish a person had delivered it

It costs an awful lot of money to give away a kidney

hotspot

Study links childhood stress with decline in older age

At least 12 people were injured in a blast at a port in northwest Turkey

Pharma showers House GOP doctor with campaign cash

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

The a glaring gap in research on serious mental illness and primary care

Group behind ProMed defends move to subscription

focus

focus

leisure time

Wikipedia